Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors
International Journal of Urology · 2026
DOI: 10.1111/iju.70382 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yuki Nemoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokiwakai Jyoban Hospital, Fukushima, Japan. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Nephrectomy, Immune Checkpoint Inhibitors. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Tokyo Women's Medical University.
Abstract (Originalsprache)
Objective
Treatment outcomes for metastatic renal cell carcinoma (mRCC) have significantly improved with immune checkpoint inhibitors (ICIs); however, optimal treatment strategies remain incompletely defined. This study evaluated treatment outcomes in mRCC patients with intact primary renal tumors, focusing on the survival impact of cytoreductive nephrectomy (CN).
Methods
We retrospectively analyzed 104 consecutive mRCC patients (2019–2024) treated with immuno‐oncology combinations (IO+IO) or IO plus tyrosine kinase inhibitors (IO+TKI). Surgical timing was classified as upfront CN, deferred CN, or non‐CN. Landmark analyses at 6 and 12 months minimized immortal time bias. Multivariable analyses identified survival predictors.
Results
IO+IO patients were younger (63 vs. 68 years; p = 0.033) with higher progressive disease rates (31% vs. 2%), but similar objective response rates (50% vs. 47%) compared to IO+TKI. Of 104 patients, 25 underwent upfront CN, 25 deferred CN, and 54 non‐CN. Deferred CN independently predicted improved survival versus non‐CN in multivariable analysis (HR 0.17; 95% CI 0.05–0.57) and 6‐month landmark analysis (HR 0.22; 95% CI 0.06–0.83), but not at the 12‐month landmark, suggesting time‐varying effects.
Conclusions
IO+IO and IO+TKI demonstrated comparable efficacy with distinct profiles. Deferred CN may improve survival when performed within an optimal therapeutic window in selected patients, emphasizing the importance of treatment timing and response‐adapted selection in the ICI era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tokiwakai Jyoban Hospital, Fukushima, Japan.
- Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
- Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan.
- Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
- Department of Urology, Saiseikai Kazo Hospital, Saitama, Japan.
ORCID-Profile: Hiroki Ishihara, Toshio Takagi
Förderung
- Tokyo Women's Medical University
Zitieren
APA
Nemoto, Y., Ishihara, H., Fukuda, H., Yoshida, K., Iizuka, J., Shimmura, H., Hashimoto, Y., Kondo, T., Kobayashi, H., & Takagi, T. (2026). Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors. International Journal of Urology. https://doi.org/10.1111/iju.70382
Vancouver
Nemoto Y, Ishihara H, Fukuda H, Yoshida K, Iizuka J, Shimmura H, et al. Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors. International Journal of Urology. 2026. doi:10.1111/iju.70382
BibTeX
@article{Nemoto2026,
author = {Nemoto, Yuki and Ishihara, Hiroki and Fukuda, Hironori and Yoshida, Kazuhiko and Iizuka, Junpei and Shimmura, Hiroaki and Hashimoto, Yasunobu and Kondo, Tsunenori and Kobayashi, Hiroshi and Takagi, Toshio},
title = {Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70382}
}
EUVIMED